VEA
SNDX icon

Virtus ETF Advisers’s Syndax Pharmaceuticals SNDX Stock Holding History

Virtus ETF Advisers’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,278
Closed -$69.8K – 749
2024
Q4 		$69.8K Buy
5,278
+827
+19% +$14.2K 0.03% 379
2024
Q3 		$85.7K Buy
4,451
+78
+2% +$1.61K 0.04% 403
2024
Q2 		$89.8K Buy
4,373
+14
+0.3% +$293 0.04% 359
2024
Q1 		$104K Sell
4,359
-298
-6% -$6.65K 0.06% 357
2023
Q4 		$101K Buy
4,657
+125
+3% +$1.92K 0.06% 355
2023
Q3 		$65.8K Sell
4,532
-451
-9% -$8.53K 0.04% 395
2023
Q2 		$104K Buy
4,983
+863
+21% +$18K 0.06% 361
2023
Q1 		$87K Sell
4,120
-1,581
-28% -$39.3K 0.05% 369
2022
Q4 		$145K Sell
5,701
-927
-14% -$21.6K 0.08% 355
2022
Q3 		$159K Buy
6,628
+44
+0.7% +$987 0.06% 345
2022
Q2 		$127K Sell
6,584
-2,139
-25% -$35.6K 0.05% 366
2022
Q1 		$152K Sell
8,723
-515
-6% -$8.67K 0.07% 226
2021
Q4 		$202K Sell
9,238
-2,003
-18% -$37K 0.08% 205
2021
Q3 		$215K Sell
11,241
-594
-5% -$9.9K 0.09% 251
2021
Q2 		$203K Buy
11,835
+7
+0.1% +$128 0.08% 336
2021
Q1 		$264K Buy
11,828
+204
+2% +$4.61K 0.11% 273
2020
Q4 		$259K Sell
11,624
-8,270
-42% -$172K 0.11% 300
2020
Q3 		$294K Sell
19,894
-2,702
-12% -$41.2K 0.15% 230
2020
Q2 		$335K Buy
+22,596
New +$344K 0.16% 278

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Virtus ETF Advisers's SNDX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Syndax Pharmaceuticals (SNDX) in Q1 2025, closing a stake of 5,278 shares — an estimated $69.8K sold.

Virtus ETF Advisers first reported a position in SNDX in Q2 2020 and held it in 19 quarters. The position peaked at $335K in Q2 2020. 218 funds tracked by Wall St. Rank hold SNDX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining Syndax Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 5,278 Syndax Pharmaceuticals shares in Q1 2025, an estimated $69.8K.
  • Virtus ETF Advisers first reported a position in Syndax Pharmaceuticals in Q2 2020 and held it in 19 quarters.
  • Virtus ETF Advisers's Syndax Pharmaceuticals position peaked at $335K in Q2 2020.
  • 218 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.